A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2014
This article has no abstract
Epistemonikos ID: 37e225f0cd0898515c6b20cb6af20f81c0f87fc4
First added on: Feb 06, 2025